Retatrutide is one of the most talked-about compounds in weight-loss and metabolic research right now, mostly because of the results reported in its clinical trials. Here’s a plain-language look at what it actually is, how it’s thought to work, and what the research does and doesn’t show so far. This article is for informational purposes only.
What Is Retatrutide?
Retatrutide (development code LY3437943) is a synthetic peptide developed by Eli Lilly. It belongs to a newer class of compounds called triple hormone receptor agonists, meaning it’s designed to act on three different hormone signals in the body at once instead of just one or two, which is what most older drugs in this category do.
Clinical trial protocols have used once-weekly administration. Retatrutide remains an investigational compound in Phase 3 clinical development and is not an approved medicine anywhere.
What Retatrutide Research Has Reported
Everything below describes findings reported in clinical trials, not approved uses:
- Weight loss. In the Phase 2 obesity trial, participants on the highest dose lost an average of about 24% of their starting body weight over 48 weeks. Eli Lilly has since reported larger average weight loss from its Phase 3 program, with figures of around 28% at the highest dose.
- Blood sugar control. In a Phase 2 trial in people with type 2 diabetes, HbA1c (a measure of average blood sugar) fell by roughly 1.3 to 2.0 percentage points across the higher doses, compared with almost no change on placebo.
- Liver fat. In a substudy of people with obesity and fatty liver disease, close to 9 in 10 participants on the higher doses had liver fat back in the normal range after 48 weeks.
- Blood pressure and cholesterol. Trial data also reported changes in blood pressure and LDL (“bad”) cholesterol alongside weight loss.
- Knee osteoarthritis pain. A Phase 3 trial has reported reductions in osteoarthritis pain, studied in the context of substantial weight reduction and reduced joint strain.
How Does It Work?
Retatrutide is designed to target three separate hormone receptors at the same time, which is why it’s called a triple agonist:
| Receptor Target | What It’s Linked To |
|---|---|
| GLP-1 | Appetite regulation and insulin release after eating |
| GIP | Insulin response and fat metabolism |
| Glucagon | Energy expenditure and stored-fat metabolism |
Older drugs in this category, like semaglutide, target the GLP-1 receptor. Tirzepatide targets two receptors, GLP-1 and GIP. Retatrutide is designed to add a third, the glucagon receptor, based on the idea that acting on all three pathways may produce a different combined metabolic effect than targeting one or two alone.
See also: The Molecule With Three Jobs
Dosing in Clinical Research
Retatrutide isn’t an approved medicine, so there’s no official human dose, and this guide won’t provide one. What can be described is how clinical trials have approached dosing. Participants started on lower doses and moved up gradually over several weeks, a pattern called dose escalation, with 12 mg once weekly among the highest doses studied. Those schedules describe supervised trial protocols only, not a recommendation.
Why Retatrutide Is Studied in Diabetes and Weight Research
The connection becomes clearer once the receptor biology is considered. GLP-1, GIP, and glucagon aren’t only involved in blood sugar regulation. They are also tied to appetite, energy balance, and fat metabolism. Acting on these receptors can therefore produce overlapping metabolic effects, which is why retatrutide has been studied in both type 2 diabetes and obesity trials, and why related compounds such as semaglutide and tirzepatide have been investigated across similar areas.
How Retatrutide Compares with Related Compounds
Trial results reported for retatrutide include larger weight-change figures than those reported in some studies of older single- or dual-receptor drugs. The important limitation is that results from separate trials should not be treated as if they came from one direct comparison.
| Drug | Receptors Targeted | Reported Average Weight Loss in Trials |
|---|---|---|
| Semaglutide | GLP-1 only | Up to roughly 15% of body weight |
| Tirzepatide | GLP-1 and GIP | Up to roughly 20% of body weight |
| Retatrutide | GLP-1, GIP, and glucagon | Up to roughly 24 to 28% of body weight |
The catch is that these numbers come from separate trials with different participants and designs, not a single head-to-head study comparing all three compounds directly. Larger numbers in separate trials are a signal for further research, not conclusive proof of greater effectiveness in a fair, direct comparison.
See also: Retatrutide vs Tirzepatide, What Sets Them Apart
What Conditions Retatrutide Is Being Studied For
Retatrutide is being studied across several areas. These are research indications, not approved uses:
- Obesity and chronic weight management. One of the largest areas of clinical research and the source of much of the attention around the compound.
- Type 2 diabetes. Studied for effects on blood sugar control alongside changes in body weight.
- Knee osteoarthritis in people with obesity. Studied in the context of whether substantial weight reduction may affect joint strain and related symptoms.
- Obstructive sleep apnea. Studied in connection with metabolic and body-weight changes.
- Fatty liver disease (MASLD, formerly called NAFLD). Studied through liver fat measurements in people with obesity.
What Are Retatrutide’s Side Effects or Risks?
The most commonly reported side effects in trials have been digestive, including nausea, vomiting, diarrhea, and constipation, and they have tended to be dose-dependent. Because retatrutide is still investigational, researchers are continuing to evaluate its longer-term safety profile. Related drugs in this class have been associated with risks including pancreatitis and gallbladder disease, which are among the issues monitored in retatrutide trials as well.
FAQ
Is retatrutide approved by the FDA?
No. Retatrutide is an investigational compound in Phase 3 clinical development and has not been approved as a medicine by the FDA or any other regulator.
Is retatrutide the same thing as semaglutide or tirzepatide?
No. Semaglutide targets one hormone receptor (GLP-1), tirzepatide targets two (GLP-1 and GIP), and retatrutide targets three (GLP-1, GIP, and glucagon).
How much weight did people lose in retatrutide trials?
About 24% average weight loss at 48 weeks in the highest-dose Phase 2 group, with Eli Lilly reporting figures of around 28% at the highest dose in its Phase 3 program. These figures come from specific trial populations and protocols rather than an approved-use standard.
Is retatrutide safe?
Its long-term safety profile is still being studied. Digestive side effects are among the most commonly reported findings in trials so far, while researchers continue to evaluate less common and longer-term risks.
Research Use Disclaimer
This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations.
Sources
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet. 2023;402(10401):529-544.
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048.
- Wikipedia. Retatrutide, its structure, mechanism, and clinical trial history.
- Eli Lilly and Company. What to Know About Retatrutide, official overview of its investigational status and trial results.
- American Diabetes Association. Newsroom release on Phase 2 retatrutide trial results presented at the 83rd Scientific Sessions.
- Drugs.com. Retatrutide development history and regulatory timeline.
